Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancer Hiroyasu Yokomise, MD, Masashi.

Slides:

Advertisements

Similar presentations

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Advertisements

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Stephen R. Broderick, MD, MPHS

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management Delphine Trousse, MD, Fabrice Barlesi,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

E-cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer Dage Liu, MD, Cheng-long Huang, MD, Kotaro.

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Lung cancer screening: No more excuses

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Ground glass opacity of the lung: The veil that needs lifting

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy Morihito Okada, MD, Hiroyuki Yamagishi,

William M. DeCampli, MD, PhD

How should we treat air leaks?

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum Martin Czerny, MD, MBA The Journal.

Thymoma with idiopathic thrombocytopenic purpura: Report of a case

The lord of the rings Antonio Miceli, MD, PhD

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Yang Zhang, MD, Haiquan Chen, MD, PhD

Aditya K. Kaza, MD The Journal of Thoracic and Cardiovascular Surgery

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Military surgeons just want to have fun

A first start for lung transplantation?

Required area of lymph node sampling during segmentectomy for clinical stage IA non– small cell lung cancer Hiroaki Nomori, MD, PhD, Yasuomi Ohba, MD,

Stephen R. Broderick, MD, MPHS

The Journal of Thoracic and Cardiovascular Surgery

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Development of a canine model of pulmonary emphysema and imaging of the emphysematous lung with infrared thoracoscopy Masashi Gotoh, MD, Taku Okamoto,

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

In search of the smoking gun in calcific aortic valve disease

Cardiac surgery in patients with a porcelain aorta

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Commentary: Do the right thing! Ethical versus legal

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Functional tricuspid pathology: To treat or not to treat

Problems related to TNM staging: Patients with stage III non–small cell lung cancer Kotaro Kameyama, MD, Cheng-long Huang, MD, Dage Liu, MD, Taku Okamoto,

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

First nights, the adrenal axis, and steroids

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

The continuing challenge of congenital heart disease in China

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Apples remain apples NO matter what

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Preoperative PFTs: The answer is blowing in the wind

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Journal changes and initiatives

Impact of neoadjuvant chemoradiotherapy followed by surgical resection on node- negative T3 and T4 non–small cell lung cancer Benedict D.T. Daly, MD,

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancer Hiroyasu Yokomise, MD, Masashi Gotoh, MD, Taku Okamoto, MD, Yasumichi Yamamoto, MD, Shinya Ishikawa, MD, Takashi Nakashima, MD, Daiki Masuya, MD, Dage Liu, MD, Cheng-long Huang, MD The Journal of Thoracic and Cardiovascular Surgery Volume 133, Issue 5, Pages 1179-1185 (May 2007) DOI: 10.1016/j.jtcvs.2006.12.039 Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Representative computed tomographic findings of bulky cN2 mediastinal lymph nodes. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 1179-1185DOI: (10.1016/j.jtcvs.2006.12.039) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Overall survival for all 41 cases. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 1179-1185DOI: (10.1016/j.jtcvs.2006.12.039) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Overall survival according to chemotherapy protocol. TXL, Paclitaxel; TXT, docetaxel. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 1179-1185DOI: (10.1016/j.jtcvs.2006.12.039) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Overall survival according to pathologic response. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 1179-1185DOI: (10.1016/j.jtcvs.2006.12.039) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Overall survival of patients with persistent pN2 disease according to pathologic response. The Journal of Thoracic and Cardiovascular Surgery 2007 133, 1179-1185DOI: (10.1016/j.jtcvs.2006.12.039) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions